MedTrace Logo

MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

NCT06980506 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-05-22

No results posted yet for this study

Summary

The purpose of this Expanded Access Program (EAP) is to allow use of the investigational imaging agent, MNPR-101-DFO\*-89Zr, with positron emission tomography/computed tomography (PET/CT) imaging, to non-invasively detect the presence of urokinase plasminogen activator receptor (uPAR) binding in solid tumors. uPAR binding is higher in tumors compared to normal tissue in some cancers.

Conditions

Interventions

DIAGNOSTIC_TEST

MNPR-101-DFO*-89Zr

MNPR-101-DFO\*-89Zr is an antibody radionuclide conjugate intended to image solid tumors expressing uPAR.

Sponsors & Collaborators

  • Monopar Therapeutics

    lead INDUSTRY

Principal Investigators

  • Ebrahim S. Delpassand, M.D. Chairman & Medical Director, Nuclear Medicine · Excel Diagnostics & Nuclear Oncology Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06980506 on ClinicalTrials.gov